Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro) compared with Novo Nordisk’s semaglutide (Wegovy) 2.4mg in 700 adult participants who have obesity or overweight with weight related comorbidities without Type 2 diabetes.
The study, ‘A Study of Tirzepatide in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)’, has the primary outcome of percent weight change from baseline in body weight over a 72-week period. The study will have secondary measures including ≥10%, ≥15%, ≥20%, ≥25% and >30body weight reduction, change from baseline in waist circumference in cms, change from baseline in body mass index and percent change from baseline in body weight, all over a 72-week period.
According to the filing on the ClinicalTrials.gov website, the study has an estimated start of 28 April 2023 and an estimated primary completion date of March 2025.
For more information, please visit the ClinicalTrials.gov website here